TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Published

Journal Article

PURPOSE: TMPRSS2-ERG gene fusion was recently reported as the most common gene rearrangement in prostate cancer (PCA). RESULTS: In this cohort 41% of the patients showed positive gene fusion status in their PCA. The TMPRSS2-ERG gene fusion status was homogenous within the same cancer focus and 82% of fusion positive PCA were present in GS 6 or 7 vs. 14% in GS 8 (p = 0.004). Moreover, TMPRSS2-ERG fusion was present in 42% of Gleason pattern 3 vs. 27% of Gleason pattern 4 (p = 0.014). However, in this study, no significant association was noticed between TMPRSS2-ERG fusion status in relation to pathological stage, surgical margin or biochemical failure. EXPERIMENTAL DESIGN: Using break-apart FISH assay to indirectly assess the fusion of TMPRSS2-ERG. We sought to characterize the incidence, pathological features and clinical parameters of TMPRSS2-ERG gene fusion in a cohort of 196 Canadian men treated by radical prostatectomy for localized PCA, and to investigate its potential as a biomarker in PCA. CONCLUSION: The higher association of TMPRSS2-ERG with Gleason score 6 and 7 should be further investigated. If confirmed, this could have significant clinical impact in further stratifying patients with PCA should the TMPRSS2-ERG be confirmed as a prognostic biomarker.

Full Text

Duke Authors

Cited Authors

  • Darnel, AD; Lafargue, CJ; Vollmer, RT; Corcos, J; Bismar, TA

Published Date

  • January 2009

Published In

Volume / Issue

  • 8 / 2

Start / End Page

  • 125 - 130

PubMed ID

  • 19029822

Pubmed Central ID

  • 19029822

Electronic International Standard Serial Number (EISSN)

  • 1555-8576

Digital Object Identifier (DOI)

  • 10.4161/cbt.8.2.7134

Language

  • eng

Conference Location

  • United States